Ali Nsair |
Ali Nsair |
New Faculty Physician Scientist |
Medical School Loan Repayment Program |
$120,312 |
Reza Ardehali |
Reza Ardehali |
New Faculty Physician Scientist |
Medical School Loan Repayment Program |
$35,511 |
Buck Institute for Age Research |
Xianmin Zeng |
Research Training II |
CIRM Research Training Program in Stem Cells and Aging |
$1,472,416 |
Cal State Univ, Long Beach |
Lisa Klig |
Bridges |
CIRM Stem Cell Research Biotechnology Training Program at CSULB |
$3,487,091 |
Tippi C. Mackenzie |
Tippi Mackenzie |
New Faculty Physician Scientist |
Medical School Loan Repayment Program |
$36,436 |
University of California, Santa Cruz |
David Haussler |
Research Training II |
UCSC CIRM Training Program in Systems Biology of Stem cells |
$4,397,002 |
The University Corporation at California State University, Northridge |
Cindy Malone |
Bridges |
CSUN-UCLA Bridges to Stem Cell Research |
$3,814,078 |
Salk Institute for Biological Studies |
Juan Carlos Izpisua Belmonte |
Research Training II |
Training in the Biology of Human Embryonic Stem Cells and Emerging Technologies II |
$2,886,221 |
Cal State Univ, Sacramento |
Lisa Hammersley |
Bridges |
Strengthening the Pipeline of Masters-level Scientific and Laboratory Personnel in Stem Cell Research |
$3,057,754 |
Stanford University |
Theo Palmer |
Research Training II |
Stanford CIRM Training Program |
$7,017,629 |
Cal State Univ, San Bernadino |
Nicole Bournias-Vardiabasis |
Bridges |
CSUSB Bridges to Stem Cell Research |
$2,762,085 |
Scripps Research Institute |
Jeanne Loring |
Tools and Technologies I |
The Stem Cell Matrix: a map of the molecular pathways that define pluripotent cells |
$1,133,552 |
University of California, Berkeley |
David Schaffer |
Tools and Technologies I |
Directed Evolution of Novel AAV Variants for Enhanced Gene Targeting in Pluripotent Human Stem Cells and Investigation of Dopaminergic Neuron Differentiation |
$918,000 |
University of California, Irvine |
Orhan NALCIOGLU |
Tools and Technologies I |
A MULTI-MODALITY MOLECULAR IMAGING SYSTEM (MRSPECT) FOR IN VIVO STEM CELL TRACKING |
$719,798 |
University of California, Los Angeles |
Hsian-Rong Tseng |
Tools and Technologies I |
Microfluidic Platform for Screening Chemically Defined Conditions that Facilitate Clonal Expansion of Human Pluripotent Stem Cells |
$914,096 |
University of California, Los Angeles |
Michael Phelps |
Tools and Technologies I |
Novel Tools and Technologies for Translational PET Imaging of Cell-based Therapies |
$914,039 |
Fluidigm Corporation |
Marc Unger |
Tools and Technologies I |
Scaleup of Versatile, Fully Automated, Microfluidic Cell Culture System |
$749,518 |
Gamma Medica-Ideas, Inc. |
Douglas Wagenaar |
Tools and Technologies I |
A Novel SPECT Microscopy System for 3D Imaging of Single Stem Cells In Vivo |
$800,065 |
Vala Sciences, Inc. |
Patrick McDonough |
Tools and Technologies I |
Optimization in the Identification, Selection and Induction of Maturation of Subtypes of Cardiomyocytes derived from Human Embryonic Stem Cells |
$870,717 |
University of Southern California |
Pin Wang |
Tools and Technologies I |
Development of Baculoviral Vectors for Gene Editing of Human Stem Cells |
$945,604 |
University of California, Merced |
Michael Cleary |
Tools and Technologies I |
RNA Analysis by Biosynthetic Tagging (RABT): a tool for the identification of cell type-specific RNAs |
$481,096 |
University of California, Santa Barbara |
Dennis Clegg |
Tools and Technologies I |
Synthetic Matrices for Stem Cell Growth and Differentiation |
$599,404 |
University of California, Berkeley |
Steven Conolly |
Tools and Technologies I |
Magnetic Particle Imaging: A Novel Ultra-sensitive Imaging Scanner
for Tracking Stem Cells In Vivo |
$858,345 |
City of Hope, Beckman Research Institute |
Larry Couture |
Tools and Technologies I |
Development of Suspension Adaptation, Scale-up cGMP Banking and Cell Characterization Technologies for hESC Lines |
$882,929 |
University of California, San Diego |
Steve Dowdy |
Tools and Technologies I |
TAT Cell-Permeable Protein Delivery of siRNAs for Epigenetic Programming of Human Pluripotent and Adult Stem Cells |
$720,000 |
University of California, Irvine |
Lisa Flanagan |
Tools and Technologies I |
Novel Separation of Stem Cell Subpopulations |
$861,122 |
ViaCyte, Inc. |
Evert Kroon |
Tools and Technologies I |
Development of the Theracyte Cellular Encapsulation System for Delivery of human ES Cell-derived Pancreatic Islets and Progenitors. |
$827,072 |
University of California, Santa Cruz |
Joel Kubby |
Tools and Technologies I |
AO Wide-Field Microscope |
$549,551 |
University of California, Davis |
Kit Lam |
Tools and Technologies I |
Discovery of adhesion ligands for pluripotent human stem cells |
$834,003 |
Stanford University |
Helen Blau |
Tools and Technologies I |
Regulation of Stem Cell Fate in Bioengineered Arrays of Hydrogel Microwells |
$949,608 |
Scripps Research Institute |
Carlos Barbas |
Tools and Technologies I |
Development of a novel technology for precise, efficient, and safe genetic modification of stem cells |
$1,138,548 |
VistaGen Therapeutics, Inc. |
Kristina Bonham |
Tools and Technologies I |
Development of an hES Cell-Based Assay System for Hepatocyte Differentiation Studies and Predictive Toxicology Drug Screening |
$971,558 |
University of California, San Diego |
Ying Liu |
Tools and Technologies I |
Generation of disease models for neurodegenerative disorders in hESCs by gene targeting |
$709,829 |
University of California, Davis |
Alice Tarantal |
Tools and Technologies I |
In Vivo Imaging for the Detection and Quantitation of Transplanted Stem/Progenitor Cells in Nonhuman Primates |
$799,350 |
Vitalant Research Institute |
Elizabeth Read |
Conference |
Translation of Stem Cell Therapies: Best Practices and Regulatory Considerations |
$30,000 |
Children's Hospital of Orange County |
Philip Schwartz |
Conference |
Stem Cell Therapies for Pediatric Diseases and Injuries: A Critial Evaluation |
$786 |
University of California, San Diego |
Catriona Jamieson |
New Faculty II |
Derivation and Characterization of Myeloproliferative Disorder Stem Cells from Human ES Cells |
$3,065,572 |
University of California, Irvine |
Edwin Monuki |
New Faculty II |
Mechanisms in Choroid Plexus Epithelial Development |
$2,793,395 |
University of Southern California |
Gage DeKoeyer Crump |
New Faculty II |
Skeletogenic Neural Crest Cells in Embryonic Development and Adult Regeneration of the Jaw |
$2,247,403 |
University of California, San Francisco |
Jeremy Reiter |
New Faculty II |
High throughput modeling of human neurodegenerative diseases in embryonic stem cells |
$2,259,092 |
University of California, Los Angeles |
Antoni Ribas |
New Faculty II |
Stem Cells for Immune System Regeneration to Fight Cancer |
$3,072,000 |
University of California, Merced |
Kara McCloskey |
New Faculty II |
Building Cardiac Tissue from Stem Cells and Natural Matrices |
$1,656,083 |
Gladstone Institutes, J. David |
Benoit Bruneau |
New Faculty II |
Induction of cardiogenesis in pluripotent cells via chromatin remodeling factors |
$2,723,653 |
University of California, Davis |
Paul Knoepfler |
New Faculty II |
Molecular mechanisms governing hESC and iPS cell self-renewal and pluripotency |
$2,157,255 |
University of California, Los Angeles |
Brigitte Gomperts |
New Faculty II |
Stem Cells in Lung Cancer |
$2,381,572 |
University of California, Berkeley |
Lin He |
New Faculty II |
The roles of non-coding RNAs in the self-renewal and differentiation of pluripotent stem cells |
$1,406,823 |
Ludwig Institute for Cancer Research |
Bing Ren |
New Faculty II |
Mechanisms of chromatin dynamics at enhancers during ES cell differentiation |
$1,726,564 |
University of California, San Diego |
Mana Parast |
New Faculty II |
Molecular Mechanisms of Trophoblast Stem Cell Specification and Self-Renewal |
$3,077,918 |
University of California, San Diego |
Shyni Varghese |
New Faculty II |
A Novel Microenvironment-Mediated Functional Skeletal Muscle from Human Embryonic Stem Cells and their In Vivo Engraftment |
$2,300,569 |
University of California, San Francisco |
Ophir Klein |
New Faculty II |
Laying the groundwork for building a tooth: analysis of dental epithelial stem cells |
$3,075,251 |
University of California, San Francisco |
Robert Blelloch |
New Faculty II |
Mechanisms of small RNA regulation in early embryonic development |
$2,790,695 |
University of California, San Francisco |
Emmanuelle Passegue |
New Faculty II |
Mechanisms Underlying the Responses of Normal and Cancer Stem Cells to Environmental and Therapeutic Insults |
$2,124,488 |
Children's Hospital of Los Angeles |
Tracy Grikscheit |
New Faculty II |
Mechanism of Tissue Engineered Small Intestine Formation |
$3,211,122 |
University of Southern California |
Qilong Ying |
New Faculty II |
Mechanisms Underlying the Diverse Functions of STAT3 in Embryonic Stem Cell Fate Regulation |
$2,261,174 |
University of California, San Francisco |
Holger Willenbring |
New Faculty II |
Molecular dissection of adult liver regeneration to guide the generation of hepatocytes from pluripotent stem cells |
$2,832,008 |
San Diego State University Foundation |
Ricardo Zayas |
New Faculty II |
The molecular basis underlying adult neurogenesis during regeneration and tissue renewal |
$1,712,225 |
Gladstone Institutes, J. David |
Yadong Huang |
New Faculty II |
Defining the Isoform-Specific Effects of Apolipoprotein E on the Development of iPS Cells into Functional Neurons in Vitro and in Vivo |
$2,757,303 |
University of California, San Diego |
Benjamin Yu |
New Faculty II |
Regulation of Adult Stem Cell Proliferation by RAS and Cell-Permeable Proteins |
$3,017,978 |
Stanford University |
Ching-Pin Chang |
New Faculty II |
VEGF signaling in adventitial stem cells in vascular physiology and disease |
$3,005,695 |
UCSF Benioff Children’s Hospital Oakland |
Mark Walters |
Disease Team Planning |
CIRM Disease Team Planning Award |
$16,939 |
Sanford Burnham Prebys Medical Discovery Institute |
Zhuohua Zhang |
New Cell Lines |
Derivation of Parkinson's Disease Coded-Stem Cells (PD-SCs) |
$1,556,448 |
Cedars-Sinai Medical Center |
Eduardo Marbán |
Disease Team Planning |
{REDACTED} Heart Disease Regenerative Medicine Team Planning Award |
$38,980 |
Stanford University |
Julie Baker |
New Cell Lines |
Derivation of hESC Lines with Disease Lesions |
$1,404,725 |
University of California, Irvine |
Leslie Thompson |
Disease Team Planning |
Huntington's Disease Team |
$41,953 |
Stanford University |
Michele Calos |
New Cell Lines |
Safe, efficient creation of human induced pluripotent stem cells without the use of retroviruses |
$1,406,875 |
Children's Hospital of Los Angeles |
Donald Kohn |
Disease Team Planning |
STEM CELL GENE THERAPY FOR SICKLE CELL DISEASE |
$12,131 |
University of California, Los Angeles |
Amander Clark |
New Cell Lines |
Generation of Pluripotent Cell Lines from Human Embryos |
$1,167,416 |
University of California, San Francisco |
Jeffrey Bluestone |
Disease Team Planning |
A CIRM Disease Team for the Treatment and Cure of Diabetes |
$55,000 |
Sanford Burnham Prebys Medical Discovery Institute |
Mark Mercola |
Disease Team Planning |
"Stem Cell Therapies for Heart Failure" |
$44,450 |
Gladstone Institutes, J. David |
Bruce Conklin |
New Cell Lines |
Induced Pluripotent Stem Cells for Cardiovascular Diagnostics |
$1,708,560 |
University of Southern California |
David Woodley |
Disease Team Planning |
Clinical Regenerative Wound Healing With Stem Cells |
$33,626 |
City of Hope, Beckman Research Institute |
Michael Barish |
Disease Team Planning |
Genetically-modified neural stem cells for treatment of high-grade glioma |
$55,000 |
University of California, San Diego |
Steve Dowdy |
New Cell Lines |
Protein transduction of transcription factors: a non-genetic approach to generate new pluripotent cell lines from human skin. |
$1,073,585 |
University of California, San Francisco |
Jeffrey Lotz |
Disease Team Planning |
A CIRM Disease Team for the Repair of Traumatically Injured and Arthritic Cartilage |
$33,172 |
University of California, San Diego |
Dennis Carson |
Disease Team Planning |
CIRM Planning Grant in Leukemia |
$52,174 |
University of California, San Francisco |
Susan Fisher |
New Cell Lines |
Optimization of Human Embryonic Stem Cell Derivation Techniques and Production/Distribution of GMP-Grade Lines |
$1,383,419 |
University of Southern California |
Mark Humayun |
Disease Team Planning |
Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) |
$3,088 |
Stanford University |
Robert Robbins |
Disease Team Planning |
{REDACTED} Cardiovascular Regenerative Team |
$25,119 |
Gladstone Institutes, J. David |
Robert Farese |
New Cell Lines |
Establishment of Frontotemporal Dementia Patient-Specific Induced Pluripotent Stem (iPS) Cell Lines with Defined Genetic Mutations |
$1,696,424 |
Salk Institute for Biological Studies |
Samuel Pfaff |
Disease Team Planning |
Motor neuron diseases: Finding cures through basic, translational, and clinical collaboration |
$51,266 |
University of California, Los Angeles |
Stanley Carmichael |
Disease Team Planning |
Development of a Stem Cell Therapy to Promote Functional Recovery in Stroke |
$42,748 |
Salk Institute for Biological Studies |
Fred Gage |
New Cell Lines |
Development of Induced Pluripotent Stem Cells for Modeling Human Disease |
$1,737,720 |
Gladstone Institutes, J. David |
Deepak Srivastava |
Disease Team Planning |
Pluripotent Stem Cell–Based Therapy for Heart Disease |
$13,505 |
University of California, San Francisco |
Long-cheng Li |
New Cell Lines |
Induction of pluripotent stem cells by small RNA-guided transcriptional activation |
$1,368,461 |
ViaCyte, Inc. |
Emmanuel Baetge |
Disease Team Planning |
Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes |
$48,950 |
University of Southern California |
Martin Pera |
New Cell Lines |
New Technology for the Derivation of Human Pluripotent Stem Cell Lines for Clinical Use |
$1,266,134 |
Stanford University |
Michael Longaker |
New Cell Lines |
Derivation and analysis of pluripotent stem cell lines with inherited TGF-b mediated disorders from donated IVF embryos and reprogrammed adult skin fibroblasts |
$1,406,636 |
University of California, San Diego |
Lawrence Goldstein |
Disease Team Planning |
Human Stem Cell Approaches to Alzheimers Disease Therapies |
$55,000 |
Scripps Research Institute |
Sheng Ding |
New Cell Lines |
Derivation of New ICM-stage hESCs |
$936,973 |
University of California, San Francisco |
Miguel Ramalho-Santos |
New Cell Lines |
Somatic cell age and memory in the generation of iPS cells |
$1,307,201 |
University of California, Los Angeles |
Irvin Chen |
Disease Team Planning |
Stem Cell Therapy for AIDS- Disease Team Planning |
$51,490 |
Stanford University |
Renee Reijo Pera |
New Cell Lines |
Derivation and comparative analysis of human pluripotent ESCs, iPSCs and SSCs: Convergence to an embryonic phenotype |
$1,409,243 |
Buck Institute for Age Research |
Xianmin Zeng |
Disease Team Planning |
Develop a cell replacement therapy for Parkinson's disease using human embryonic stem cells |
$37,161 |
Gladstone Institutes, J. David |
Sheng Ding |
New Cell Lines |
Derivation of New ICM-stage hESCs |
$778,859 |
University of California, Irvine |
Henry Klassen |
Disease Team Planning |
Stem cells for neuroprotection of photoreceptors in retinitis pigmentosa |
$23,537 |
University of California, Irvine |
Leslie Thompson |
New Cell Lines |
New Cell Lines for Huntington's Disease |
$1,302,526 |
Ludwig Institute for Cancer Research |
Webster Cavenee |
Disease Team Planning |
Stem Cell-Mediated Oncocidal Therapy of Primary & Metastatic Brain Tumors |
$3,867 |
University of California, Los Angeles |
Zack Jerome |
New Cell Lines |
Generation of clinical grade human iPS cells |
$1,341,000 |
University of California, Santa Barbara |
Glenn Lucas |
Major Facilities |
UC Santa Barbara Bio Sciences II |
$3,205,800 |
University of California, Santa Cruz |
Margaret Delaney |
Major Facilities |
UC Santa Cruz IBSC Facility |
$7,191,950 |